Liquidia Technologies (LQDA) Stock Price, News & Analysis

Company Overview

Liquidia Technologies, Inc. is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH). LIQ861 aims to offer a more convenient and potentially more consistent dosing approach compared with current liquid-based nebulized therapies. Besides PAH, Liquidia is exploring additional indications and dosage forms to expand the use of its PRINT platform, including collaborations focused on vaccine adjuvants and other respiratory applications.

Liquidia Technologies was founded to translate advanced particle-engineering science into therapeutic benefit and has assembled a team with experience in respiratory drug development, regulatory affairs and clinical operations. The company conducts clinical research primarily in the United States, and it plans to pursue regulatory filings in major markets following the completion of pivotal studies. Under the leadership of President and CEO Chris Critelli, Liquidia continues to advance its pipeline toward potential commercialization.

Key Stats

• Today's Range: $28.07 to $28.90
• 50-Day Range: $12.00 to $29.22
• 52-Week Range: $8.75 to $29.94
• Volume: 232,283 shs
• Average Volume: 1.81 million shs
• Market Capitalization: $2.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.11
• Consensus Rating: Buy

Liquidia Technologies Stock Analysis - MarketRank™

Liquidia Technologies scored higher than 62% of companies evaluated by MarketBeat, and ranked 400th out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Buy

Consensus Rating

Liquidia Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Liquidia Technologies has a consensus price target of $32.11, representing about 11.3% upside from its current price of $28.85.

Amount of Analyst Coverage

Liquidia Technologies has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Liquidia Technologies are expected to grow in the coming year, from ($1.51) to ($1.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Liquidia Technologies is -16.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Liquidia Technologies is -16.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Liquidia Technologies has a P/B Ratio of 31.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

21.36% of the outstanding shares of Liquidia Technologies have been sold short.

Short Interest Ratio / Days to Cover

Liquidia Technologies has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Liquidia Technologies has recently decreased by 12.88%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Liquidia Technologies does not currently pay a dividend.

Dividend Growth

Liquidia Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

21.36% of the outstanding shares of Liquidia Technologies have been sold short.

Short Interest Ratio / Days to Cover

Liquidia Technologies has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Liquidia Technologies has recently decreased by 12.88%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.30

News Sentiment

Liquidia Technologies has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 30 news articles for Liquidia Technologies this week, compared to 7 articles on an average week.

Search Interest

7 people have searched for LQDA on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Liquidia Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,514,890.00 in company stock.

Percentage Held by Insiders

30.10% of the stock of Liquidia Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.54% of the stock of Liquidia Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LQDA Stock Analysis - Frequently Asked Questions

How have LQDA shares performed this year?

Liquidia Technologies' stock was trading at $11.76 at the beginning of the year. Since then, LQDA stock has increased by 145.3% and is now trading at $28.85.

How were Liquidia Technologies' earnings last quarter?

Liquidia Technologies, Inc. (NASDAQ:LQDA) posted its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.06. The company's revenue for the quarter was up 141.5% on a year-over-year basis.
Read the conference call transcript.

When did Liquidia Technologies IPO?

Liquidia Technologies (LQDA) raised $50 million in an initial public offering on Thursday, July 26th 2018. The company issued 4,500,000 shares at a price of $10.00-$12.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who are Liquidia Technologies' major shareholders?

Liquidia Technologies' top institutional shareholders include Opaleye Management Inc. (2.87%), Geode Capital Management LLC (1.64%), Tyro Capital Management LLC (1.45%) and CenterBook Partners LP (1.29%). Insiders that own company stock include Caligan Partners Lp, Roger Jeffs, Russell Schundler, Paul B Manning, Michael Kaseta, Rajeev Saggar, Scott Moomaw, Robert A Lippe, Dana Boyle, Jason Adair, Sarah Krepp and Raman Singh.
View institutional ownership trends.

How do I buy shares of Liquidia Technologies?

Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Liquidia Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Liquidia Technologies investors own include JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Ford Motor (F), Predictive Oncology (POAI), Tesla (TSLA), Advanced Micro Devices (AMD) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/08/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LQDA
• CIK: 1819576
• Web: www.liquidia.com
• Phone: (919) 328-4400
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Liquidia Technologies: $32.11
• High Price Target: $43.00
• Low Price Target: $13.00
• Potential Upside/Downside: +11.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$130.39 million
• Net Margins: -732.17%
• Pretax Margin: -784.54%
• Return on Equity: -232.96%
• Return on Assets: -60.81%

Debt

• Debt-to-Equity Ratio: 9.84
• Current Ratio: 2.49
• Quick Ratio: 2.41

Sales & Book Value

• Annual Sales: $14 million
• Price / Sales: 177.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.91 per share
• Price / Book: 31.70

Miscellaneous

• Outstanding Shares: 86,090,000
• Free Float: 60,178,000
• Market Cap: $2.48 billion
• Optionable: Optionable
• Beta: 0.22